Amanda Wagner is the President and CEO of Immunitas and was a founding member of the company at its launch in 2019. During her time at Immunitas, she has contributed to the company’s fundraising efforts totaling nearly $100 million; led the structuring and negotiation of multiple strategic collaborations with leading academic institutions; and driven the advancement of the lead asset IMT-009, a CD161 inhibitor, and robust pipeline based on the company’s proprietary discovery engine. Prior to joining Immunitas, she was Vice President of Corporate Development at Q32 Bio, where she contributed to the company’s $46 million Series A. Previously, Amanda was at Concert Pharmaceuticals, where she managed a $250 million asset sale, directly contributed to the Initial Public Offering, and identified and led the development of a preclinical therapeutic for autoimmune disease, now in Phase 3. Prior to Concert, Amanda was an early member of the team at UpToDate, Inc. She also sits on the Board of Directors of the National Alopecia Areata Foundation. Amanda has a master’s degree in business administration from the Simmons School of Management.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related